Health Canada provided conditional approval of Ibrance (palbociclib) for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer as initial endocrine-based therapy for metastatic disease. The Health Canada approval of Ibrance is based on the final results of the phase II PALOMA-1/TRIO 18 trial (n=165), which studied...
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
